Table 1 Effects of test agents on baseline MSAP, HR and power density of vasomotor components of SAP spectrum in RVLM
Treatment | Maximal changes in | ||
|---|---|---|---|
MSAP(mmHg) | HR(bpm) | Power Density(mmHg 2 ) | |
aCSF | +3.8 ± 0.5 | +4.7 ± 0.9 | +0.6 ± 0.7 |
ICI 182780 (0.25 pmol) | +4.3 ± 0.4 | +5.2 ± 0.6 | +0.6 ± 0.6 |
ICI 182780 (0.5 pmol) | +4.5 ± 0.5 | +5.5 ± 0.3 | +0.7 ± 0.5 |
R,R-THC (50 pmol) | +4.6 ± 0.7 | +5.7 ± 0.8 | +0.8 ± 0.7 |
MPP (1 nmol) | +5.3 ± 0.7 | +5.1 ± 1.1 | +0.8 ± 0.3 |
AMD (5 nmol) | −4.2 ± 0.6 | +2.4 ± 1.2 | −0.6 ± 0.7 |
AMD (10 nmol) | −4.5 ± 0.6 | −3.4 ± 1.5 | −0.6 ± 0.5 |
LY294002 (5 pmol ) | +3.0 ± 0.7 | −4.4 ± 1.0 | +0.7 ± 0.6 |
Akt inhibitor (250 pmol) | +2.8 ± 0.8 | +4.0 ± 0.8 | +0.8 ± 0.4 |
AdGFP (5 × 108 pfu) | −4.1 ± 0.8 | +5.1 ± 1.2 | −0.7 ± 0.6 |
AdPTEN (5 × 108 pfu) | −4.8 ± 1.1 | +5.7 ± 1.0 | −1.0 ± 0.5 |
ERα ASON (250 pmol) | +5.5 ± 0.5 | +5.5 ± 1.2 | +0.6 ± 0.5 |
ERβ ASON (250 pmol) | +5.4 ± 1.0 | +4.6 ± 1.1 | +0.7 ± 0.7 |
ERα SCR (250 pmol) | +4.1 ± 0.8 | +3.6 ± 1.0 | +0.8 ± 0.7 |
ERβ SCR (250 pmol) | +4.9 ± 0.7 | −3.9 ± 0.6 | +0.7 ± 0.5 |